MARY KRETCHMAN: Open Payments
NPI 1164203006 · OAKLAND, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$877 in 40 payments from 13 companies in 2025. Trend: 2023 $54 · 2024 $833 · 2025 $877
Food & beverage: $877
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 6 | $303 |
| ABBVIE INC. | 16 | $231 |
| Astellas Pharma US Inc | 3 | $68 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $58 |
| Exact Sciences Corporation | 2 | $35 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $32 |
| Axsome Therapeutics, Inc. | 2 | $30 |
| Merck Sharp & Dohme LLC | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| PFIZER INC. | 1 | $20 |
Products named: AIRSUPRA, FARXIGA, QULIPTA, VRAYLAR, Veozah, Kerendia, JARDIANCE, Auvelity.
Industry payments across MD — which companies pay providers there.
